Publications by authors named "W Jonat"

Claim this Profile
B
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Mario Campone, Seock-Ah Im, Hiroji Iwata, Mark Clemons, Yoshinori Ito, Walter Jonat

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of physical activity on the immune system in breast cancer patients during chemotherapy.
Thorsten Schmidt, Walter Jonat, Daniela Wesch, Hans-Heinrich Oberg, Sabine Adam-Klages

J Cancer Res Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Antonia Wenners, Jana Grambach, Juliane Koss, Nicolai Maass, Walter Jonat

BMC Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
José Baselga, Seock-Ah Im, Hiroji Iwata, Javier Cortés, Michele De Laurentiis, Walter Jonat

Lancet Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility study to evaluate compliance of physical activity over a long time period and its influence on the total activity score, glucose metabolism and physical and psychological parameters following breast cancer.
Thorsten Schmidt, Madalena Schwarz, Marion Van Mackelenbergh, Walter Jonat, Burkhard Weisser

Mol Clin Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis